Can miR-145-5p be used as a marker in diabetic patients?

References

• Barutta, F., et al., 2013. Urinary exosomal MicroRNAs in incipient diabetic nephropathy. PLoS One, 8 (11), e73798.
   PubMed Web of Science ®Google Scholar
• Chakraborty, C., et al., 2014. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley interdisciplinary reviews: RNA, 5 (5), 697–712.
   PubMed Web of Science ®Google Scholar
• Chauhan, A. and Sharma, S., 2016. Comments on: Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian journal of endocrinology and metabolism, 20 (6), 881–882.
   PubMedGoogle Scholar
• Cheng, F., et al., 2020. Aberrant expression of miR-214 is associated with obesity-induced insulin resistance as a biomarker and therapeutic. Diagnostic pathology, 15 (1), 18.
   PubMed Web of Science ®Google Scholar
• Cui, C., et al., 2016. miR-145 regulates diabetes-bone marrow stromal cell-induced neurorestorative effects in diabetes stroke rats. Stem cells translational medicine, 5 (12), 1656–1667.
   PubMed Web of Science ®Google Scholar
• Deiuliis, J.A., 2016. MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. International journal of obesity, 40 (1), 88–101.
   Web of Science ®Google Scholar
• Deshpande, A.D., Harris-Hayes, M., and Schootman, M., 2008. Epidemiology of diabetes and diabetes-related complications. Physical Therapy, 88 (11), 1254–1264.
   PubMed Web of Science ®Google Scholar
• Faruq, O. and Vecchione, A., 2015. microRNA: diagnostic perspective. Frontiers in medicine, 2, 51.
   PubMed Web of Science ®Google Scholar
• Flor, L.S. and Campos, M.R., 2017. The prevalence of diabetes mellitus and its associated factors in the Brazilian adult population: evidence from a population-based survey. Revista Brasileira de epidemiologia, 20 (1), 16–29.
   PubMedGoogle Scholar
• He, M., et al., 2020. miR-145 improves metabolic inflammatory disease through multiple pathways. Journal of molecular cell biology, 12 (2), 152–162.
   PubMed Web of Science ®Google Scholar
• Honardoost, M., et al., 2019. Network of three specific microRNAs influence type 2 diabetes through inducing insulin resistance in muscle cell lines. Journal of cellular biochemistry, 120 (2), 1532–1538.
   Web of Science ®Google Scholar
• Jiménez-Lucena, R., et al., 2018. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study. Molecular therapy - nucleic acids, 12, 146–157.
   Google Scholar
• Karalliedde, J. and Gnudi, L., 2016. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrology dialysis transplantation, 31 (2), 206–213.
   PubMed Web of Science ®Google Scholar
• Karolina, D.S., et al., 2012. Circulating miRNA profiles in patients with metabolic syndrome. Journal of clinical endocrinology and metabolism, 97 (12), E2271–E2276.
   PubMed Web of Science ®Google Scholar
• Negrato, C. and Tarzia, O., 2010. Buccal alterations in diabetes mellitus. Diabetology and metabolic syndrome, 2, 3.
   PubMed Web of Science ®Google Scholar
• Ogurtsova, K., et al., 2017. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinical practice, 128, 40–50.
   PubMed Web of Science ®Google Scholar
• Paul, P., et al., 2018. Interplay between miRNAs and human diseases. Journal of cellular physiology, 233 (3), 2007–2018.
   PubMed Web of Science ®Google Scholar
• Riches, K., et al., 2014. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype. Journal of molecular and cellular cardiology, 74, 240–250.
   PubMed Web of Science ®Google Scholar
• Russo, F., et al., 2016. Circulating noncoding RNAs as clinical biomarkers. In J.L. García-Giménez, ed. Epigenetic biomarkers and diagnostics. London, UK: Academic Press, 239–258.
   Google Scholar
• Sharma, S., Mathew, A.B., and Chugh, J., 2017. miRNAs: nanomachines that micromanage the pathophysiology of diabetes mellitus. Advances in clinical chemistry, 82, 199–264.
   PubMed Web of Science ®Google Scholar
• Shi, B., et al., 2007. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. Journal of biological chemistry, 282 (45), 32582–32590.
   PubMed Web of Science ®Google Scholar
• Shyu, K.G., Cheng, W.P., and Wang, B.W., 2015. Angiotensin II downregulates MicroRNA-145 to regulate kruppel-like factor 4 and myocardin expression in human coronary arterial smooth muscle cells under high glucose conditions. Molecular Medicine, 21 (1), 616–628.
   PubMedGoogle Scholar
• Sridhar, G. and Gumpeny, L., 2016. Epigenetics and diabetes. In: G. Sridhar, ed. Advances in diabetes: novel insights. JP Medical, 81.
   Google Scholar
• Steffensen, L.B., et al., 2018. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients. Cardiovascular diabetology, 17 (1), 72.
   PubMedGoogle Scholar
• Su, J., et al., 2014. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One, 9 (12), e114420.
   PubMed Web of Science ®Google Scholar
• Sun, K. and Lai, E.C., 2013. Adult-specific functions of animal microRNAs. Nature Reviews Genetics, 14 (8), 535–548.
   PubMed Web of Science ®Google Scholar
• Trzybulska, D., Vergadi, E., and Tsatsanis, C., 2018. MiRNA and other non-coding RNAs as promising diagnostic markers. EJIFCC, 29 (3), 221–226.
   PubMedGoogle Scholar
• Zeinali, T., et al., 2019. Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomedicine and Pharmacotherapy, 109, 195–207.
   PubMed Web of Science ®Google Scholar